DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for endometrial stromal sarcoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrial stromal sarcoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrial stromal sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Endometrial stromal sarcoma accounts for about 1% of all uterine cancers and less than 10% of all uterine mesenchymal neoplasms. A 2013 review covering 86 studies, of which 84 were retrospective, one was a prospective phase II trial, and one was a phase III randomised study, concluded that the value of adjuvant therapy for early-stage disease remains unproven. Hysterectomy and bilateral salpingo-oophorectomy is the cornerstone of treatment for stage I or II disease, and surgical resection when feasible may also be appropriate for advanced-stage tumours. Hormone therapy continues to be described as the most efficacious treatment modality for patients with advanced-stage or recurrent disease.
A 2023 case report from Morocco describes a 66-year-old woman with low-grade stromal endometrial sarcoma treated with surgery and endocrine therapy, but provides no quantitative outcome data such as survival or response duration. A 2013 case report of a 78-year-old woman with a very late recurrence of a formerly misdiagnosed low-grade endometrial stromal sarcoma metastasised to the colon notes that these tumours have a high tendency for recurrence and that long-term follow-up is required. No numbers of patients or survival figures are given in either case report.
A 2024 literature review on radiotherapy for endometrial stromal sarcoma states that radiotherapy serves as an adjuvant treatment and may improve disease-free survival and increase patient survival, but also notes that there are studies which still require large-scale prospective studies to validate its effectiveness. The review does not report specific survival rates, response rates, or sample sizes from any individual study. For early-stage disease, the review says radiotherapy may not be necessary, but it can be considered for cases with metastasis or when surgery is not an option.
What is still missing are prospective randomised trials with adequate sample sizes to determine whether adjuvant radiotherapy or any specific hormone therapy regimen improves overall survival or progression-free survival in defined subgroups. The rarity of the tumour makes such trials difficult to fund and complete. Patient stratification by grade (low versus high) and by hormone receptor status is not systematically addressed in the available evidence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2013 · 105 citations
Endometrial Stromal Sarcoma
AbstractOBJECTIVE: To summarize available studies with respect to evaluation and management of patients with endometrial stromal sarcoma and undifferentiated endometrial sarcoma. DATA SOURCES: We conducted an electronic search of research articles published in English between January 1, 1981, and January 1, 2013, using MEDLINE, PubMed, and ClinicalTrials.gov (www.clinicaltrials.gov) databases. METHODS OF STUDY SELECTION: Of the 115 studies initially identified, 86 were chosen after limiting the review to those articles focusing on endometrial stromal sarcoma and crossreferencing to eliminate duplication. Review articles were excluded. Of the 86 studies meeting eligibility criteria, 84 were retrospective, one was a prospective phase II trial, and one was a phase III randomized study. Data were extracted systematically. Each of the reviewers assessed the quality of each study independently. TABULATION, INTEGRATION, AND RESULTS: Data were abstracted using standard abstraction templates to summarize study findings. Given the rarity of this tumor, we report available data with respect to epidemiology, pathogenesis, prognostic factors, and treatment. Endometrial stromal sarcoma and undifferentiated endometrial sarcoma comprise an estimated 1% of all uterine cancers and less than 10% of all uterine mesenchymal neoplasms. Hysterectomy and bilateral salpingo-oophorectomy is the cornerstone of treatment for early-stage (I or II) disease. Surgical resection when feasible may also be appropriate for patients presenting with advanced-stage tumors. The value of adjuvant therapy for early-stage disease remains unproven. Hormone therapy continues to be the most efficacious treatment modality for patients with advanced-stage or recurrent disease. CONCLUSION: Endometrial stromal sarcoma and undifferentiated endometrial sarcoma are rare tumors. Surgical resection is appropriate for patients with early-stage (I or II) disease and those with resectable, advanced-stage (III or IV) tumors. Hormone therapy may be appropriate in treating advanced and recurrent disease.
International Journal of Surgery Case Reports · 2013 · 8 citations · open access
A very late recurrence of a formerly misdiagnosed low grade endometrial stromal sarcoma metastasized to the colon
AbstractINTRODUCTION: Endometrial stromal sarcomas are rare mesenchymal neoplasms of the uterus with an indolent clinical course but a high risk of recurrence. PRESENTATION OF CASE: We report a case of a 78 year old woman who presented with rectal bleeding and recurrent urinary tract infections, caused by a very late recurrence of a formerly misdiagnosed low grade endometrial stromal sarcoma, metastasized to the colon. DISCUSSION: Endometrial stromal sarcomas are difficult to diagnose, both due to the rarity of the tumor and because of the close resemblance of the tumor to normal stromal tissue. These tumors are known for a high tendency of recurrence, therefore long term follow up is required in patients with endometrial stromal sarcoma. CONCLUSION: In patients with a history known for endometrial stromal sarcoma recurrence should always be considered.
High-grade endometrial stromal sarcoma with YWHAE-NUTM2B fusion gene abnormality identified after 10 years of recurrent pulmonary metastases: A case report
Abstract•Endometrial stromal sarcoma is the second most common type of uterine sarcoma.•Endometrial stromal sarcoma has undergone modifications since its proposal.•This case highlights the importance of accurately diagnosing endometrial stromal sarcoma.•Asymptomatic uterine fibroids may not be treated with therapeutic intervention or prompt regular check-ups.
International Journal of Medical Reviews and Case Reports · 2023 · 0 citations · open access
Long term disease control under aromatase inhibitor for advanced low grade stromal endometrial carcinoma: Case Repot from a tertiary care hospital in Morocco.
AbstractLow-grade stromal endometrial sarcoma (ESS) is a rare type of uterine cancer that arises from the stromal cells of the endometrium, which is the inner lining of the uterus. It is a subtype of endometrial stromal sarcoma, which is a group of tumors that are characterized by the presence of cells that resemble the normal stromal cells of the endometrium. The optimal management of low-grade ESS is not well established, but surgical resection followed by adjuvant hormonal therapy or chemotherapy may be considered depending on the patient's individual characteristics. we report the case of a 66 years old women, diagnosed with a low grade stromal endometrial sarcoma, treated in our tertiary hospital with surgery and endocrine therapy.
International Journal of Radiology and Imaging · 2024 · 0 citations · open access
RADIATION THERAPY FOR ENDOMETRIAL STROMAL SARCOMA: A LITERATURE REVIEW
AbstractBackground: Endometrial Stromal Sarcoma (ESS) is a part of uterine sarcoma that can clinically manifest with abnormal vaginal bleeding, postmenopausal bleeding, uterine enlargement or mass, dysmenorrhea, pelvic pressure, or pain. ESS is divided into four main categories: endometrial stromal nodule, low-grade ESS, high-grade ESS, and undifferentiated uterine sarcoma. Management for ESS includes surgery, chemotherapy, radiotherapy, and hormone therapy. We want to review the role of radiation therapy for endometrial stromal sarcoma, from several pieces of literature. Material and Methods: We are conducting a literature review to describe the role of radiation therapy for ESS. Results: Radiotherapy serves as an adjuvant treatment in ESS, potentially improving prognosis and survival rates. While early-stage ESS may not necessitate radiotherapy, it can be considered for ESS cases with metastasis or when surgery is not an option. Conclusion: According to previous studies, radiotherapy for ESS can improve disease-free survival and increase patient survival. On the other hand, there are studies that still require large-scale prospective studies to validate the effectiveness of radiotherapy for ESS. Keywords: Endometrial Stromal Sarcoma, Radiotherapy, Effectiveness
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
